Immunovant, Inc. announced that it has signed a purchase agreement with existing investor Roivant Sciences Ltd. to issue 17,021,276 shares at a price of $11.75 per share for the gross proceeds for $199,999,993 on August 2, 2021. The investor stake has increased from 57.5% to 63.8% stake in the company. The issuance and sale of the Shares is exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.06 USD | +1.61% | +5.54% | -1.69% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.69% | 8.77B | |
+25.88% | 653B | |
+27.00% | 556B | |
-6.62% | 354B | |
+20.38% | 331B | |
+2.91% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-5.89% | 144B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Immunovant, Inc. announced that it has received $199.999993 million in funding from Roivant Sciences Ltd.